Discovery & history

• Why adding a glucagon arm to GLP-1 changes what the drug can do
• How survodutide is engineered for once-weekly dosing
• What the obesity and MASH trials actually measured, tier by tier
• How it compares with semaglutide, tirzepatide, retatrutide, and the earlier dual agonists
• How to read its investigational status, dosing framing, and safety honestly

1. 01 Discovery & history The obesity drug that borrows a second hormone free
2. 02 Chemistry, structure & pharmacokinetics How a glucagon backbone becomes a once-weekly drug paid
3. 03 Dual GLP-1 and glucagon receptor mechanism Two receptors, two organs, one weekly signal paid
4. 04 The glucagon advantage What the second hormone actually buys you paid
5. 05 Obesity: the weight-loss evidence From a dose-finding trial to a Phase 3 result paid
6. 06 MASH: the liver evidence The liver data that made survodutide stand out paid
7. 07 The clinical trial program How survodutide was tested, step by step paid
8. 08 The incretin landscape: how it compares Where survodutide sits among the metabolic drugs paid
9. 09 Regulatory status and the road ahead Investigational today, and what comes next paid
10. 10 Dosing & administration How survodutide is dosed in trials, for education only paid
11. 11 Safety & tolerability What is known about safety, and what is not paid
12. 12 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

Survodutide did not appear from nowhere. The body already makes a natural dual GLP-1 and glucagon agonist called oxyntomodulin, and in 2009 two labs showed that engineering one molecule to hit both receptors could reverse obesity in mice far beyond what a GLP-1-only agonist achieved. That insight kicked off the modern co-agonist field, and survodutide is one of the molecules it produced.

Read the timeline as a slow build from a mouse experiment to a human obesity trial. The concept is 17 years old, but the clinical proof arrived only recently, and much of the Phase 3 program has not yet reported. That gap between an old idea and young human data is a theme this course keeps returning to.

Strip away the branding and survodutide is a 29-amino-acid peptide derived from glucagon, with a fatty-acid tail bolted on so it lasts for days rather than minutes in the body. It is dosed as a once-weekly injection under the skin. The two cards below anchor the basic facts and put its weight result beside the drugs it gets compared with.

Read those bars as four separate trials, not as a race. They ran for different lengths, in different populations and eras, and they do not all report the same estimand, so the distance between two bars is not a treatment effect. What the bars do show is that survodutide is not the biggest number in the class, which is why its case rests on a different mechanism rather than a bigger figure, and that is what the next page unpacks.

The whole point of survodutide is that its two receptor arms do different work. The GLP-1 arm handles the familiar appetite and blood-sugar effects shared by every drug in this class. The glucagon arm adds something GLP-1 alone cannot: a direct signal to the liver to burn fat and spend more energy. The two panels lay the arms side by side.

Holding both arms in view prevents the most common mistake about survodutide: treating it as a slightly stronger semaglutide. It is not stronger, it is additive in a different direction. The useful question is what the second receptor adds, not how one dose compares with another, a distinction this course builds on throughout.

Survodutide sits in an unusual spot: strong Phase 2 data and two positive Phase 3 obesity readouts, in adults without and with type 2 diabetes, but no approval, no cardiovascular outcome trial reported, and no long-term safety record. The honest ceiling keeps those apart. What is genuinely well supported today is narrower than the online enthusiasm suggests, and the four tiers below separate proven from promising from purely hoped-for.

A handful of claims dominate the online conversation about survodutide. Held against the actual trials, most are not simply false so much as overstated: a real effect gets rounded up or stripped of its qualifier. Tap each claim to see the honest verdict and its evidence tier, and notice how often the fix is a number or a caveat rather than a flat yes or no.

The recurring theme is proportion, not truth. Survodutide really does lower weight and improve liver biopsies; the distortion is one of size, certainty, and availability. Learning to attach the right qualifier to a real effect is the core literacy skill this course builds, and it matters most for a drug people are hearing about before they can legally get it.